Evidence map›Paper›PMID 35841099›Full record

ArticleJournal of neuroinflammation2022

Increased levels of a pro-inflammatory IgG receptor in the midbrain of people with schizophrenia.

A Petty, L J Glass, D A Rothmond, T Purves-Tyson, A Sweeney, Y Kondo, S Kubo, M Matsumoto, C Shannon Weickert

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

A PettySchizophrenia Research Laboratory, Neuroscience Research Australia, Sydney, NSW, 2031, Australia.
L J GlassSchizophrenia Research Laboratory, Neuroscience Research Australia, Sydney, NSW, 2031, Australia.
D A RothmondSchizophrenia Research Laboratory, Neuroscience Research Australia, Sydney, NSW, 2031, Australia.
T Purves-TysonSchizophrenia Research Laboratory, Neuroscience Research Australia, Sydney, NSW, 2031, Australia.
A SweeneyNSW Brain Tissue Resource Centre, University of Sydney, Sydney, NSW, 2006, Australia.
Y KondoAstellas Research Institute of America LLC, San Diego, CA, 92121, USA.
S KuboAstellas Pharma Inc., Tsukuba, Ibaraki, 305-8585, Japan.
M MatsumotoAstellas Research Institute of America LLC, San Diego, CA, 92121, USA.
C Shannon WeickertSchizophrenia Research Laboratory, Neuroscience Research Australia, Sydney, NSW, 2031, Australia. cyndi@neura.edu.au.
Neuroscience Research Australia · AUAstellas Pharma (United States) · USUNSW Sydney · AUAstellas Pharma (Japan) · JPUniversity of Sydney · AU

Funding

Brain Tissue Resource Centre for Alcohol ResearchR28AA012725 · NIAAA · UNIVERSITY OF SYDNEY · PI Greg Trevor Sutherland · 2012 to 2026
$7.0M
NIAAA NIH HHS R28 AA012725
6 · The paper itself

Abstract

backgroundThere is growing evidence that neuroinflammation may contribute to schizophrenia neuropathology. Elevated pro-inflammatory cytokines are evident in the midbrain from schizophrenia subjects, findings that are driven by a subgroup of patients, characterised as a "high inflammation" biotype. Cytokines trigger the release of antibodies, of which immunoglobulin G (IgG) is the most common. The level and function of IgG is regulated by its transporter (FcGRT) and by pro-inflammatory IgG receptors (including FcGR3A) in balance with the anti-inflammatory IgG receptor FcGR2B. Testing whether abnormalities in IgG activity contribute to the neuroinflammatory abnormalities schizophrenia patients, particularly those with elevated cytokines, may help identify novel treatment targets.

methodsPost-mortem midbrain tissue from healthy controls and schizophrenia cases (n = 58 total) was used to determine the localisation and abundance of IgG and IgG transporters and receptors in the midbrain of healthy controls and schizophrenia patients. Protein levels of IgG and FcGRT were quantified using western blot, and gene transcript levels of FcGRT, FcGR3A and FcGR2B were assessed using qPCR. The distribution of IgG in the midbrain was assessed using immunohistochemistry and immunofluorescence. Results were compared between diagnostic (schizophrenia vs control) and inflammatory (high vs low inflammation) groups.

resultsWe found that IgG and FcGRT protein abundance (relative to β-actin) was unchanged in people with schizophrenia compared with controls irrespective of inflammatory subtype. In contrast, FcGRT and FcGR3A mRNA levels were elevated in the midbrain from "high inflammation" schizophrenia cases (FcGRT; p = 0.02, FcGR3A; p < 0.0001) in comparison to low-inflammation patients and healthy controls, while FcGR2B mRNA levels were unchanged. IgG immunoreactivity was evident in the midbrain, and approximately 24% of all individuals (control subjects and schizophrenia cases) showed diffusion of IgG from blood vessels into the brain. However, the intensity and distribution of IgG was comparable across schizophrenia cases and control subjects.

conclusionThese findings suggest that an increase in the pro-inflammatory Fcγ receptor FcGR3A, rather than an overall increase in IgG levels, contribute to midbrain neuroinflammation in schizophrenia patients. However, more precise information about IgG-Fcγ receptor interactions is needed to determine their potential role in schizophrenia neuropathology.

Indexed as

SchizophreniaCytokinesHumansImmunoglobulin GInflammationMesencephalonReceptors, IgGRNA, MessengerCytokinesImmunoglobulin GReceptors, IgGRNA, MessengerAntibodiesAntibody receptorFcGR3AInflammationMidbrainPost-mortemSchizophrenia

Identifiers

PMID35841099
PMCPMC9287858
OpenAlexW4285490843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.